Improve Human Health to Preserve Patients’ Dignity

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Asieris Received NMPA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

January 16, 2025

Asieris Received NMPA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors

January 12, 2025

Asieris Pharmaceuticals Appoints Helen Xu as Chief Commercial Officer

January 6, 2025

Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program

November 17, 2024

Asieris Pharmaceuticals Appoints Joanna Zhang as Chief Medical Officer

November 12, 2024

Asieris Unveils Results for the First Time at 2024 IPVC the Analysis of the of HPV Clearance Rate for Different HPV Types and Different Follow-up Times of the Non-Surgical Treatment for Cervical HSIL Product APL-1702 Clinical Study

November 7, 2024

Asieris Hong Kong and SPH Keyuan Trade Sign Strategic Cooperation Agreement at CIIE

Technology Platform